https://www.selleckchem.com/pr....oducts/itacitinib-in
No severe or unexpected adverse events were reported. This study demonstrated the long-term safety and efficacy of the PCL-filler, with safety confirmed for up to 30 months. This study demonstrated the long-term safety and efficacy of the PCL-filler, with safety confirmed for up to 30 months. Although various treatments are currently available for primary cutaneous amyloidosis (PCA), there is no entirely satisfactory treatment. Recently, fractional ablative lasers are claimed to have therapeutic effects for PCA. To evaluate
Like
Comment
Share
